Earlier this year (April 2025), Lilly reported positive Phase III results for orforglipron, an oral small-molecule (non-peptide) GLP-1 receptor agonist, for treating Type 2 diabetes and obesity
Most families with members suffering from carnitine deficiency, systemic primary have been identified to harbor private mutations
In the two feeding groups, the feeding strategy was the same as that in the previous 6 weeks
The escalation timelines differ
Free from allergens and additives: it contains NO allergens (lactose, gluten, gelatine, soy), artificial colourings (TiO2), preservatives or other undesired additives
Further tests can confirm whether a person is pregnant.